08:43 AM EDT, 07/15/2026 (MT Newswires) -- Ascelia Pharma (ACE.ST) said Wednesday that Chief Financial Officer Anton Hansson will leave the company in the latter part of August. The Swedish oncology-focused biotechnology company will trim its cost base and focus on bringing Orviglance to patients in light of the organizational change and cost-cutting initiatives. Orviglance is a novel oral contrast agent designed for magnetic resonance imaging of the liver.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.